Your session is about to expire
← Back to Search
Diabetes Homeless Medication Support (D-Homes) for Type 2 Diabetes (D-HOMES Trial)
Phase 2
Waitlist Available
Led By Katherine D Vickery, MD, MSc
Research Sponsored by Hennepin Healthcare Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 30 weeks
Awards & highlights
D-HOMES Trial Summary
This trial will compare the effects of a diabetes medication intervention to brief diabetes education on homeless people with diabetes.
Eligible Conditions
- Type 2 Diabetes
- Housing Insecurity
- Psychological Distress
D-HOMES Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to 30 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 30 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Experience during the intervention
Retention in assessments
Secondary outcome measures
Change in glycemic control
Diabetes medication adherence
Psychological wellness
D-HOMES Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: D-Homes interventionExperimental Treatment2 Interventions
Behavioral treatments by a diabetes wellness coach as defined below.
Group II: Enhanced usual careActive Control1 Intervention
Brief diabetes educational session by a diabetes wellness coach.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enhanced usual care
2017
Completed Phase 4
~10570
Diabetes Homeless Medication Support (D-Homes)
2022
Completed Phase 2
~50
Find a Location
Who is running the clinical trial?
Hennepin Healthcare Research InstituteLead Sponsor
90 Previous Clinical Trials
77,139 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,356 Previous Clinical Trials
4,315,028 Total Patients Enrolled
Katherine D Vickery, MD, MScPrincipal InvestigatorHennepin Healthcare Research Institute
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Enhanced usual care
- Group 2: D-Homes intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any opportunities for participants in this clinical research endeavor?
"According to clinicaltrials.gov, this specific medical trial is no longer seeking participants—the initial posting was on February 23rd 2022 and the most recent update coming from November 15th 2022. There are however 1451 other studies in search of individuals at present."
Answered by AI
Has the FDA sanctioned Diabetes Homeless Medication Support (D-Homes) yet?
"Our team at Power have assigned Diabetes Homeless Medication Support (D-Homes) a rating of 2 due to the lack of clinical evidence in favour of its efficacy, but prior data suggesting it is safe."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger